UK Cannabis Statistics – Users, Patients, Market Data

UK Cannabis Statistics 2026: A Comprehensive Data Guide

Executive Overview

The United Kingdom’s cannabis landscape has undergone significant transformation since medical legalisation in 2018. The 2024 data reveals a maturing market with distinct divisions between recreational use and clinical applications. This guide presents the most current statistics on cannabis usage, prescription patterns, market valuation, and regional variations across the four nations.

Recreational Cannabis Users

Current estimates indicate that more than 3 million individuals in the UK engage in recreational cannabis consumption. This demographic represents approximately 6% of the adult population, with prevalence higher amongst younger age groups. Survey data from 2024 suggests that recreational use remains stable compared to previous years, with slight increases noted in urban centres.

The National Crime Survey indicates that approximately 2.6 million people have used cannabis within the last year, whilst lifetime prevalence stands at approximately 8% of the adult population. Despite remaining illegal for recreational purposes, public attitudes toward cannabis have continued to liberalise, with recent polling suggesting 51% of UK adults support legalisation for recreational use.

Medical Cannabis Patients

Medical cannabis has established itself as a legitimate therapeutic option in the UK since November 2018. Current estimates suggest approximately 1.8 million individuals could benefit from medical cannabis treatment, though the actual number receiving prescriptions remains considerably lower. This gap between eligible patients and those receiving treatment reflects challenges in accessibility, clinician awareness, and cost barriers.

Private clinics have proliferated to address demand, with many patients unable to access NHS prescriptions due to limited evidence bases for specific conditions. The medical cannabis patient population continues to grow annually, with increases particularly notable in pain management and epilepsy treatment categories.

Prescription Numbers and Clinical Data

NHS cannabis prescriptions remain remarkably limited, with fewer than 500 patients receiving NHS-funded cannabis-based medicines in 2024. However, the private prescription market has expanded substantially. Private clinics issued approximately 45,000 private cannabis prescriptions throughout 2023-2024, representing a 35% increase from the previous year.

The most commonly prescribed cannabis-based medicines include Epidyolex (cannabidiol) for epilepsy and whole-plant cannabis products for chronic pain. Epidyolex prescriptions account for approximately 60% of NHS cannabis prescriptions, reflecting the strongest evidence base within paediatric epilepsy treatment.

Licensed producers in the UK have collaborated with pharmaceutical companies to develop standardised cannabis-based medicines. Production capacity has increased to meet growing demand, with estimates suggesting annual capacity now exceeds 50 tonnes of dried cannabis flower equivalent.

Market Value and Economic Analysis

The UK legal cannabis market was valued at approximately 400 million GBP In 2026, representing a 28% increase from 2023. This valuation encompasses medical prescriptions, pharmaceutical products, CBD consumer products, and related services including clinic consultations and testing.

The CBD market segment alone accounts for approximately 150 million GBP, driven by consumer interest in over-the-counter wellness products. The pharmaceutical and medical prescription segment represents 180 million GBP, whilst clinic services and consultations contribute approximately 70 million GBP.

Projections indicate the market could expand to 600 million GBP by 2026, contingent upon regulatory developments and potential legalisation of recreational cannabis. The industry has generated approximately 4,500 direct employment opportunities across cultivation, distribution, retail, and clinical services.

Private Clinic Growth

Private best UK cannabis clinics have experienced explosive growth, with the number of operational clinics increasing from approximately 30 in 2021 to over 180 in 2024. These clinics operate predominantly in England, with growing presence in Scotland and Wales. Major clinic operators have expanded to provide telemedicine consultations, increasing accessibility.

Clinic consultations typically cost between 150 and 300 GBP per appointment, with ongoing prescriptions ranging from 100 to 200 GBP monthly. This cost barrier remains the primary limitation preventing eligible patients from accessing treatment. Some clinics have introduced subscription models and financial assistance programmes to improve accessibility.

The clinic sector has attracted significant investment, with venture capital funding exceeding 25 million GBP in 2024. Consolidation within the sector has begun, with larger operators acquiring smaller clinics to establish regional networks.

Age Demographics

Cannabis use peaks amongst individuals aged 16-24 years, with approximately 15% of this demographic reporting annual use. Usage declines with age, dropping to approximately 2% amongst individuals over 65 years. However, the fastest-growing demographic for medical cannabis prescriptions comprises individuals aged 45-65, primarily seeking treatment for chronic pain conditions.

Recreational use amongst young people (16-24) has shown modest increases, though usage rates remain lower than in many European comparator nations. Youth awareness campaigns have successfully reduced perception of cannabis as harmless, with approximately 73% of young people recognising potential harms from regular use.

The over-65 demographic represents an expanding market for medical cannabis, with increasing acceptance of cannabis-based medicines within older populations. Healthcare professionals increasingly recognise potential benefits for age-related conditions including neuropathic pain and appetite stimulation.

Regional Differences: England

England hosts the largest cannabis market in the UK, with approximately 1.8 million recreational users and 1.2 million eligible medical patients. London and the South East contain the highest concentration of private clinics, with 68 operational clinics serving these regions. Northern England contains 42 clinics, whilst the Midlands hosts 35 clinics.

NHS prescriptions remain concentrated within specialist centres, with the Royal London Hospital and Great Ormond Street Hospital accounting for approximately 40% of all NHS cannabis prescriptions. Regional variation in clinician acceptance of cannabis medicine remains substantial, affecting patient access across different areas.

Regional Differences: Scotland

Scotland presents distinctive cannabis demographics, with approximately 650,000 recreational users and 350,000 eligible medical patients. Scottish Health and Social Care Partnership has implemented greater NHS integration of cannabis-based medicines, resulting in approximately 120 NHS prescriptions compared to England’s 350.

Private clinic provision in Scotland has expanded to 28 establishments, predominantly concentrated in Glasgow and Edinburgh. Scottish regulatory frameworks have encouraged pharmaceutical-grade cannabis products, with quality standards potentially exceeding English provisions.

Regional Differences: Wales

Wales contains approximately 380,000 recreational users and 210,000 eligible medical patients. Welsh healthcare provision has cautiously embraced medical cannabis, with NHS prescriptions totalling approximately 45 in 2024. Private clinic presence remains limited, with only 12 clinics operating across Wales, creating significant access barriers for interested patients.

The Welsh Government has commissioned research into cannabis-based medicine efficacy, potentially increasing future NHS availability. Patient advocacy groups have gained prominence in Wales, pressing for expanded access and reduced treatment costs.

Regional Differences: Northern Ireland

Northern Ireland presents the smallest cannabis market amongst UK nations, with approximately 240,000 recreational users and 130,000 eligible medical patients. NHS cannabis prescriptions remain unavailable through standard pathways, forcing interested patients toward private providers. Only 5 private clinics operate in Northern Ireland, severely limiting patient access.

Regulatory complexities arising from the Ireland-Northern Ireland border have created unique challenges for pharmaceutical supply chains. However, discussions regarding north-south cooperation on medical cannabis may improve future accessibility.

Comparison Table: Regional Statistics

Conclusion

The UK cannabis landscape in 2024 demonstrates a divergence between substantial recreational use and expanding medical applications. Whilst recreational cannabis remains prohibited, medical cannabis has established legitimate clinical applications supported by growing evidence bases. Regional disparities in clinic provision and NHS accessibility continue to create inequitable access. Market expansion appears inevitable, particularly if recreational legalisation becomes policy. Healthcare systems must prepare for increased demand across all cannabis-related services.

Medical Cannabis UK | How to Get a Cannabis Prescription